KSI-301: antibody biopolymer conjugate in retinal disorders
KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far hav...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-07-01
|
| Series: | Therapeutic Advances in Ophthalmology |
| Online Access: | https://doi.org/10.1177/25158414211027708 |
| _version_ | 1818641230298349568 |
|---|---|
| author | Priya R. Chandrasekaran V.G. Madanagopalan |
| author_facet | Priya R. Chandrasekaran V.G. Madanagopalan |
| author_sort | Priya R. Chandrasekaran |
| collection | DOAJ |
| description | KSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials. |
| first_indexed | 2024-12-16T23:23:52Z |
| format | Article |
| id | doaj.art-a3c508e64cf34487bb80d6f0de1100e5 |
| institution | Directory Open Access Journal |
| issn | 2515-8414 |
| language | English |
| last_indexed | 2024-12-16T23:23:52Z |
| publishDate | 2021-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Ophthalmology |
| spelling | doaj.art-a3c508e64cf34487bb80d6f0de1100e52022-12-21T22:12:04ZengSAGE PublishingTherapeutic Advances in Ophthalmology2515-84142021-07-011310.1177/25158414211027708KSI-301: antibody biopolymer conjugate in retinal disordersPriya R. ChandrasekaranV.G. MadanagopalanKSI-301 is a new intravitreal anti-vascular endothelial growth factor (VEGF) antibody biopolymer conjugate under investigation for the treatment of age-related macular degeneration (AMD), diabetic macular oedema (DME) and retinal vein occlusion (RVO). Preclinical and early clinical trials so far have shown promising results in retinal vascular diseases. When using anti-VEGF agents for treatment of retinal disorders, the frequency of injections and follow-up visits has increased the treatment burden, greatly affecting the treatment outcome. There are new anti-VEGF agents in the horizon with extended duration of action, durability, safety profile and efficacy, which seem to address the above issues. PubMed search and Medline search were performed on newer anti-VEGF agents, KSI-301, antibody biopolymer conjugate in retina, KODIAK KSI-301, DAZZLE study, GLEAM study, GLIMMER study, GLOW study and BEACON study. This review article showcases the biophysical properties and ongoing trials related to KSI-301. Moreover, we discuss the efficacy and safety profile of KSI-301 on the basis of the results of available trials.https://doi.org/10.1177/25158414211027708 |
| spellingShingle | Priya R. Chandrasekaran V.G. Madanagopalan KSI-301: antibody biopolymer conjugate in retinal disorders Therapeutic Advances in Ophthalmology |
| title | KSI-301: antibody biopolymer conjugate in retinal disorders |
| title_full | KSI-301: antibody biopolymer conjugate in retinal disorders |
| title_fullStr | KSI-301: antibody biopolymer conjugate in retinal disorders |
| title_full_unstemmed | KSI-301: antibody biopolymer conjugate in retinal disorders |
| title_short | KSI-301: antibody biopolymer conjugate in retinal disorders |
| title_sort | ksi 301 antibody biopolymer conjugate in retinal disorders |
| url | https://doi.org/10.1177/25158414211027708 |
| work_keys_str_mv | AT priyarchandrasekaran ksi301antibodybiopolymerconjugateinretinaldisorders AT vgmadanagopalan ksi301antibodybiopolymerconjugateinretinaldisorders |